Acromegaly is associated with an enhanced mortality, with cardiovascular and respiratory
complications representing not only the most frequent comorbidities but also two of the main …

Background: Somatostatin analogs (SSA) may influence glucose metabolism, but the clinical
relevance of this effect is uncertain because trials performed so far are limited in terms of …

Aliment Pharmacol Ther 2012; 35: 266–274 Summary Background Polycystic liver disease
(PLD) is a phenotypical expression of autosomal dominant polycystic kidney disease and …

Context: The effects of chronic therapy with long-acting somatostatin analogs (SSTa) on
metabolic and cardiovascular parameters have been partially elucidated in acromegalic …

Objective: The objective of the study was to investigate the impact of first-line somatostatin
analogs (SSAs) on glucose tolerance (GT) in acromegaly. Design: The design was open …

Hypothesis. The growth hormone (GH) excess displayed in acromegaly induces insulin
resistance up to diabetes mellitus (DM). The somatostatin analogues (as octreotide LAR) are …

Objective: The aim of the study was to investigate the 5-yr impact of surgery and
somatostatin analogs (SSA) on glucose metabolism in acromegaly. Design: We conducted …

To evaluate the metabolic effects of first-line somatostatin analogues or surgery in
acromegaly. Retrospective, comparative, 12-month follow-up. Two hundred and thirty one …

Objective In this study, the effect of high-dose octreotide LAR on glucose metabolism in
patients with acromegaly was investigated. Design A post-hoc analysis of a clinical trial …

Several recent studies have reported beneficial effects of pegvisomant monotherapy on
glucose homeostasis for acromegalic patients resistant to somatostatin analogs (SSA). The …